Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ASLAN Pharma says Bristol-Myers Squibb will Reacquire Cancer Drug

publication date: Aug 9, 2016
According to Singapore's ASLAN Pharma, Bristol-Myers Squibb will reacquire the rights to ASLAN002, a dual inhibitor of the cMET receptor tyrosine kinase and RON immune checkpoint. BMS will make a $10 million upfront payment and will pay up to $50 million in development and regulatory milestones. ASLAN will also be eligible to receive royalties on global sales of the molecule. ASLAN in-licensed China rights (plus selected Asian countries) to ASLAN002 in 2011. In March of this year. ASLAN reported positive results from a Phase I trial of the drug candidate. More details....

Stock Symbol: (NYSE: BMY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital